Patients with muscle-invasive bladder cancer who test positive for circulating tumor (ct)DNA after surgery to remove the ...
Enfortumab vedotin and pembrolizumab with surgery significantly improve outcomes in cisplatin-ineligible MIBC patients, ...
Enfortumab vedotin plus pembrolizumab improved EFS, OS, and pCR rates in MIBC patients ineligible for cisplatin-based chemotherapy. The combination therapy showed a median EFS and OS that were not ...
Pfizer and Japanese firm Astellas' drug Padcev, combined with Merck's Keytruda, lowered the risk of tumor recurrence, ...
The potential of moving the combination to the earlier MIBC setting significantly increases the Padcev market.
Bellmunt J, Hussain M, Gschwend JE, et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): A multicentre, open-label, randomized, phase 3 trial. Lancet ...
A New Era in the Treatment of Muscle Invasive Bladder Cancer. Discussant of LBA2 - Perioperative (Periop) Enfortumab Vedotin ...
Poorly functioning blood vessels lead to the characteristic muscle weakness that so many cancer patients experience. Artur Plawgo/Science Photo Library via Getty Images Tumors can destroy the blood ...
To kick things off, we'll set the stage on what defines non-muscle invasive bladder cancer and how we triage patient ...
Medpage Today on MSN
Another 'Practice-Changing' Study in High-Risk Bladder Cancer
BERLIN -- Adding durvalumab (Imfinzi) to bacillus Calmette-Guérin (BCG) induction and maintenance therapy significantly ...
It will explore how electronic scans of patients' body fat and muscle, combined with information about their exercise, could ...
Analyses of RNA expression reveal molecules underpinning the cancer-associated process of skeletal-muscle wasting, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback